Langar Global HealthTech ETF (LGHT)

The Langar Global HealthTech ETF (LGHT) is a thematic, actively managed fund that invests in companies worldwide that are using technology to change how healthcare is delivered, diagnosed, and monitored — spanning software platforms, medical devices, diagnostics, telemedicine, and health data analytics.

What counts as healthtech in this fund?

HealthTech is a broad church. The fund includes companies that make hardware (wearable monitors, diagnostic devices, imaging systems), software (electronic health records, practice management, pharmacy systems, data analytics), digital platforms (telemedicine, patient engagement, appointment scheduling), and pure-play diagnostic or research automation firms. The common thread is that technology is central to the business and to the business’s claim to improve healthcare efficiency, accessibility, or outcomes. A traditional pharmaceutical company does not qualify; a software maker that helps pharmaceutical companies run clinical trials does.

The fund takes a global view — holdings span the US, Europe, Asia, and other developed markets. A company need not be a household name to be included. The portfolio includes both megacap names that everyone has heard of and smaller, faster-growing, more experimental firms betting on a particular innovation.

Why this theme now?

Healthcare systems everywhere face pressure: aging populations, rising drug costs, chronic disease burden, gaps in access, and the sheer administrative friction of 20th-century workflows persisting in the 21st century. Capital is flowing toward any credible technology that can ease that burden — artificial intelligence analyzing medical images, cloud platforms that let rural clinics access specialists, wearables that catch problems early, algorithms that optimize operations. The bet underlying LGHT is that over the coming years and decades, healthcare will shift from labor-intensive and siloed to data-driven and networked, and that publicly traded tech companies are positioned to be the beneficiaries.

The risks and challenges

Thematic ETFs carry a structural tension: they are built on a bet that a particular theme will outperform, but that outperformance is never guaranteed. HealthTech is in favour now, but regulatory changes, reimbursement shifts, or simply a change in what investors believe about healthcare could reverse that. Moreover, the fund is concentrated — it holds a curated set of companies in a single vertical, not a broad market. That concentration can be a tailwind if healthtech booms; it is an anchor if the theme falls out of favour.

A secondary risk is dispersion within the theme. Some healthtech companies are profitable, growing, and taking market share; others are pre-revenue research bets or marginally profitable incumbents. The fund manager’s stock selection is the real value-add — choosing the winners from the wishful thinking. If the underlying bets do not pan out, no amount of broad exposure to the theme will save the fund.

What makes a holding win in this space?

Winners in healthtech tend to be companies with pricing power (they provide real value to healthcare providers or patients and are hard to replace), high switching costs (once hospitals or health systems adopt your software, changing out is expensive), or genuine intellectual property moats (a proprietary algorithm or dataset that competitors cannot easily replicate). A company that merely offers a nice interface to something that was already easy to do will struggle. A company that solves a real bottleneck in healthcare delivery has a shot.

How to research the fund

Start with the fact sheet and prospectus, which will list the current holdings and explain the selection criteria. Look for transparency around how the fund defines healthtech and which sub-sectors it emphasizes. Then examine the portfolio: does it seem balanced between hardware, software, and services? Are the holdings mostly large, stable names or heavily tilted toward smaller, riskier plays? Is geographic diversification real, or is it mostly US?

Historical performance against a broad health-sector index (such as the healthcare sector of the S&P 500) or against a larger healthtech ETF shows whether the fund’s selection process adds value. The expense ratio for an actively managed thematic fund is typically higher than for a passive large-cap index, so the manager’s stock picking must clear that hurdle.

For long-term investors who believe healthcare will undergo a technology-driven transformation and want exposure to that macro bet without picking individual stocks, LGHT offers a structured gateway into a complex and fast-moving vertical.